Raymond James initiated coverage of Maze Therapeutics (MAZE) with a Strong Buy rating and $48 price target Maze’s lead wholly-owned assets – MZE829 in Phase 2 study for APOL1-mediated kidney disease and MZE782 entering Phase 2 in phenylketonuria and CKD – target high unmet need chronic kidney disease populations and have “best-in-class potential,” the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics Reports Strong Q3 2025 Progress
- Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances
- Maze Therapeutics reports Q3 EPS (66c), consensus (69c)
- Maze Therapeutics Advances Kidney Disease Treatment with MZE829 Study
- Maze Therapeutics files to sell 9.23M shares of common stock for holders